Product image of Letrozolo Almus (Letrozole) supplied by GNH India

Letrozolo Almus

Active Ingredient:
Letrozole
Origin:
EU

Letrozolo Almus (Letrozole)

Letrozole, the active ingredient in Letrozolo Almus, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, where it lowers estrogen production to help control tumor growth. The medication is administered once daily and is part of standard endocrine therapy protocols.

GNH India supplies Letrozolo Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company ensures quality assurance, regulatory compliance, and reliable logistics for global healthcare partners.

Manufacturer / TM Owner

Almus S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Letrozole acts as an aromatase inhibitor and is indicated for conditions driven by estrogen signaling in breast cancer.
  • Hormone receptor‑positive breast cancer (postmenopausal): reduces tumor growth by decreasing circulating estrogen levels.
  • Adjuvant therapy for early‑stage hormone receptor‑positive breast cancer (postmenopausal): helps prevent disease recurrence after surgery.
  • Advanced or metastatic breast cancer (postmenopausal): delays progression when used alone or with other endocrine agents.

How It Works

  • Letrozole selectively and non‑competitively inhibits the aromatase enzyme, a cytochrome P450 isoform responsible for converting adrenal and ovarian androgens into estrogens in peripheral tissues. By binding to the enzyme’s active site, it blocks the final step of estrogen biosynthesis, leading to markedly reduced plasma estradiol concentrations. The resulting hypo‑estrogenic state diminishes estrogen‑driven proliferation of breast cancer cells in postmenopausal patients.

Side Effects

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Hot flashes: transient increase in body temperature sensation.
  • Joint and muscle pain: arthralgia or myalgia.
  • Nausea: mild gastrointestinal upset.
  • Fatigue: reduced energy levels.

Serious or Rare Side Effects

  • Severe liver injury: elevated transaminases or hepatitis.
  • Bone fractures: decreased bone mineral density leading to fracture risk.
  • Pulmonary embolism: formation of blood clots in the lungs.

Precautions & Warnings

When prescribing Letrozolo Almus, clinicians should observe several precautionary measures to ensure patient safety.

  • Liver function monitoring: assess baseline enzymes and repeat periodically.
  • Bone health assessment: evaluate bone mineral density and consider calcium/vitamin D supplementation.
  • Cardiovascular risk evaluation: screen for thromboembolic history and manage risk factors.
  • Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception in women of childbearing potential.
  • Drug interaction review: check concomitant medications for potential CYP interactions.
  • Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP2C19 inhibitors (e.g., fluconazole): may increase letrozole plasma levels.
  • Estrogen‑containing hormone therapy: antagonizes letrozole’s estrogen‑lowering effect.
  • Tamoxifen: concurrent use reduces therapeutic benefit of both agents.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (e.g., warfarin): letrozole may enhance anticoagulant effect, requiring INR monitoring.
  • Statins: potential for altered lipid metabolism; monitor lipid profile.
  • CYP3A4 inducers (e.g., rifampin): may lower letrozole concentrations, reducing efficacy.

Frequently Asked Questions

Letrozolo Almus contains letrozole, an aromatase inhibitor indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women. It is used in adjuvant, neoadjuvant, and metastatic settings to lower estrogen levels and help control tumor growth.

Letrozole works by selectively binding to the aromatase enzyme, which converts androgens to estrogens in peripheral tissues. By blocking this conversion, the drug markedly reduces circulating estrogen, depriving estrogen‑dependent breast cancer cells of a growth stimulus.

The specific dose of Letrozolo Almus is determined by the prescribing physician based on the patient’s clinical condition, treatment setting, and individual factors. Patients should follow the dosage instructions provided by their healthcare professional.

Letrozole is contraindicated in pregnancy because it can interfere with fetal development. Women of childbearing potential should use effective contraception while taking the medication. Safety during breastfeeding has not been established, and breastfeeding is generally not recommended.

To order Letrozolo Almus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Letrozolo Almus (letrozole) is a non‑steroidal aromatase inhibitor with a long half‑life, offering once‑daily dosing. Compared with anastrozole, it may provide slightly greater estrogen suppression, while exemestane is a steroidal inhibitor with a different safety profile. Choice of agent depends on clinical judgment, tolerability, and patient factors.

Letrozolo Almus should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain potency throughout its shelf life.

Letrozolo Almus is taken orally, usually as a tablet swallowed whole with water. It is typically administered once daily, with or without food, as directed by the prescribing clinician.

Serious risks include severe liver injury, significant bone loss leading to fractures, and rare thromboembolic events such as pulmonary embolism. Patients should be monitored regularly for liver function, bone mineral density, and any signs of clotting disorders.

Letrozolo Almus should not be used by pregnant women, individuals with known hypersensitivity to letrozole or other aromatase inhibitors, and patients with severe liver impairment without close monitoring. It is also contraindicated in premenopausal women unless ovarian suppression is medically indicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT